Objective: To identify prenatal events associated with adverse outcome in babies at less than 32 weeks of gestation in cases of cervical insufficiency and preterm labor (PTL)/premature rupture of the membranes (PROM)....Objective: To identify prenatal events associated with adverse outcome in babies at less than 32 weeks of gestation in cases of cervical insufficiency and preterm labor (PTL)/premature rupture of the membranes (PROM). Study design: A case-control study was performed using a logistic regression model at 17 tertiary hospitals in Japan. Adverse outcome was defined as neonatal death or abnormal cerebral ultrasound scans (intraventricular hemorrhage [IVH] and periventricular leukomalacia [PVL]) prior to discharge from hospital. Results: Data were analyzed for 307 cases (74 for cervical insufficiency and 233 for PTL/PROM). Neonatal death and IVH/PVL were noted in 25 and 29 cases, respectively. A significant association of cervical insufficiency (odds ratio (OR) 1.32, 95% confidence interval (CI) 1.02- 1.68), gestational age at delivery ( < 26 weeks) (OR 4.64, 95% CI 1.73- 12.44),and Apgar score < 7 at 5 min (OR 3.3, 95% CI 1.42- 7.64) with combined neonatal death or IVH and PVL was found in a logistic regression model that controlled for in utero transportation, gestational age on admission, clinical chorioamnionitis, and histopathologic chorioamnionitis. Conclusion: Cervical insufficiency is a significant factor related to the occurrence of adverse outcome.展开更多
By the end of 1980,Japanese groups had started programs with ABO-incomparible kidney transplantation as a consequence of the very limited supply of cadaveric organs for transplantation.Since then,they have done succes...By the end of 1980,Japanese groups had started programs with ABO-incomparible kidney transplantation as a consequence of the very limited supply of cadaveric organs for transplantation.Since then,they have done successful transplantations across the blood type barrier in combina-tion with plasmapheresis and splenectomy.In Japan,the strategy for ABO-incompatible transplantation has changed with the development of the tacrolimus(FK)/mycophenolate mofetil(MMF)combination in 2000 and rituximab in 2005.1 In addition,preoperative 1-week administration of FK/MMF produced much more excellent results.Current graft survival(2005-2013)was almost over 90%in both ABO-incompatible at 9-year follow-up,which was comparable to ABO-compatible kidney trans-plantations.展开更多
文摘Objective: To identify prenatal events associated with adverse outcome in babies at less than 32 weeks of gestation in cases of cervical insufficiency and preterm labor (PTL)/premature rupture of the membranes (PROM). Study design: A case-control study was performed using a logistic regression model at 17 tertiary hospitals in Japan. Adverse outcome was defined as neonatal death or abnormal cerebral ultrasound scans (intraventricular hemorrhage [IVH] and periventricular leukomalacia [PVL]) prior to discharge from hospital. Results: Data were analyzed for 307 cases (74 for cervical insufficiency and 233 for PTL/PROM). Neonatal death and IVH/PVL were noted in 25 and 29 cases, respectively. A significant association of cervical insufficiency (odds ratio (OR) 1.32, 95% confidence interval (CI) 1.02- 1.68), gestational age at delivery ( < 26 weeks) (OR 4.64, 95% CI 1.73- 12.44),and Apgar score < 7 at 5 min (OR 3.3, 95% CI 1.42- 7.64) with combined neonatal death or IVH and PVL was found in a logistic regression model that controlled for in utero transportation, gestational age on admission, clinical chorioamnionitis, and histopathologic chorioamnionitis. Conclusion: Cervical insufficiency is a significant factor related to the occurrence of adverse outcome.
文摘By the end of 1980,Japanese groups had started programs with ABO-incomparible kidney transplantation as a consequence of the very limited supply of cadaveric organs for transplantation.Since then,they have done successful transplantations across the blood type barrier in combina-tion with plasmapheresis and splenectomy.In Japan,the strategy for ABO-incompatible transplantation has changed with the development of the tacrolimus(FK)/mycophenolate mofetil(MMF)combination in 2000 and rituximab in 2005.1 In addition,preoperative 1-week administration of FK/MMF produced much more excellent results.Current graft survival(2005-2013)was almost over 90%in both ABO-incompatible at 9-year follow-up,which was comparable to ABO-compatible kidney trans-plantations.
